1 duplicate copy in the archive
EFTA Document EFTA01452451
Title Matchefta-efta01452451
Case Filesd-10-EFTA01452451Dept. of JusticeEFTA Document EFTA01452451
Unknown1p
Case File
sd-10-EFTA01452451Dept. of JusticeEFTA Document EFTA01452451
Other
in Europe. In uS, it will go generic in 2015. There is a step-down function of the royalty payments over three years according to mgmt. valuation & risks - Gilead still remains our top pick in large cap We value GILD at 5132/sh using 17x 2015 multiple (10% discount to its biotech peers due to patent cliff on base biz). Our new '15 EPS is $7.75/sh. Risks: weak sovaldi launch, poor base biz performance Please click on below link for full report: http://pull.db-gmresearch.com/p/442-7cA3/2129
Date
Unknown
Source
Dept. of Justice
Reference
sd-10-EFTA01452451
Pages
1
Persons
0
Integrity
Loading document viewer...
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.
Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.